We are live on ! Find out more
CPIX icon

Cumberland Pharmaceuticals
CPIX

48 hedge funds and large institutions have $30.1M invested in Cumberland Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

4% more funds holding

Funds holding: 46 → 48 (+2)

19% less capital invested

Capital invested by funds: $37.2M → $30.1M (-$7.13M)

33% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 15

Holders
48
Holders Change
+2
Holders Change %
+4.35%
% of All Funds
1.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
10
Reduced
15
Closed
1
Calls
$38K
Puts
–
Net Calls
+$38K
Net Calls Change
-$11K

Top Buyers

Rank Fund Capital Flow
1
SLG
Stanley-Laman Group
Pennsylvania
+$520K
2
EGA
Eagle Global Advisors
Texas
+$98.1K
3
JAM
JW Asset Management
Florida
+$68.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$11.7K
5
UBS Group
UBS Group
Switzerland
+$11.6K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$267K
2
AI
Ariel Investments
Illinois
-$131K
3
Deutsche Bank
Deutsche Bank
Germany
-$102K
4
TDC
Thompson Davis & Co
Virginia
-$89.4K
5
BIT
BlackRock Institutional Trust
California
-$16.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
26
Royce & Associates
New York
$84K – – –
GCP
27
GSA Capital Partners
United Kingdom
$78K -$267K -42,828 -76%
DAM
28
Delta Asset Management
Tennessee
$69K +$6.23K +1,000 +9%
JAM
29
JW Asset Management
Florida
$63K +$68.2K +10,939 New
Cambridge Investment Research Advisors
30
Cambridge Investment Research Advisors
Iowa
$58K – – –
RFC
31
Russell Frank Company
Washington
$30K – – –
BA
32
BlackRock Advisors
Delaware
$26K -$9.12K -1,463 -25%
NFA
33
Nationwide Fund Advisors
Ohio
$22K – – –
OC
34
Oakworth Capital
Alabama
$18K – – –
PNC Financial Services Group
35
PNC Financial Services Group
Pennsylvania
$18K – – –
OSAM
36
O'Shaughnessy Asset Management
Connecticut
$14K +$2.95K +474 +25%
WIC
37
Woodmont Investment Counsel
Tennessee
$12K – – –
UBS Group
38
UBS Group
Switzerland
$11K +$11.6K +1,860 New
BIM
39
BlackRock Investment Management
Delaware
$10K – – –
Citigroup
40
Citigroup
New York
$9K -$3.12K -500 -25%
Deutsche Bank
41
Deutsche Bank
Germany
$5K -$102K -16,299 -95%
UMA
42
USA Mutuals Advisors
Texas
$4K +$2.98K +479 +185%
Federated Hermes
43
Federated Hermes
Pennsylvania
$1K -$8.5K -1,364 -89%
GC
44
Globeflex Capital
California
$1K – – –
SEI Investments
45
SEI Investments
Pennsylvania
$1K +$75 +12 +5%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4 – – –
BRWM
47
B. Riley Wealth Management
Tennessee
– -$7K -1,000 Closed
TRCT
48
Tower Research Capital (TRC)
New York
– -$2.85K -457 -97%
1
2

CPIX Hedge Fund Activity: Q3 2015 in Review

48 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2015, worth a combined $30.1M — down 19% from $37.2M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CPIX positions and 1 closed out — a net gain of 2 holders — while 10 added to existing stakes and 15 trimmed.

The largest buyer was Stanley-Laman Group, opening a new position worth an estimated $520K. The largest seller was GSA Capital Partners, cutting an estimated $267K.

  • 48 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2015, up from 46 in Q2 2015.
  • Funds reported $30.1M of Cumberland Pharmaceuticals stock for Q3 2015, down 19% quarter-over-quarter.
  • 3 funds opened new Cumberland Pharmaceuticals positions in Q3 2015 and 1 closed out, a net change of +2 holders.
  • The largest Cumberland Pharmaceuticals buyer in Q3 2015 was Stanley-Laman Group, an estimated $520K added.
  • The largest Cumberland Pharmaceuticals seller in Q3 2015 was GSA Capital Partners, an estimated $267K sold.

Based on aggregated 13F filings for Q3 2015.